Does Rituximab (rituximab) affect blood glucose levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Rituximab's Effect on Blood Glucose Levels

Rituximab does not directly affect blood glucose levels as a primary side effect, but it can influence glucose metabolism in specific clinical scenarios through indirect mechanisms related to its immunomodulatory effects.

Main Effects on Glucose Metabolism

  • Rituximab has no direct effect on blood glucose levels listed as a common adverse effect in clinical guidelines for its use in various conditions including non-Hodgkin's lymphoma, rheumatoid arthritis, and other autoimmune conditions 1

  • Monitoring recommendations for rituximab therapy include CBC, hepatic and renal function, but do not specifically include blood glucose monitoring as a standard requirement 1

  • The primary adverse events associated with rituximab are infusion reactions, infections, and hematologic toxicities rather than metabolic disturbances 1

Special Clinical Scenarios Where Rituximab May Affect Glucose Metabolism

Beneficial Effects in Autoimmune Diabetes Conditions

  • Rituximab has shown pancreas-protective effects in acute-onset type 1 diabetes mellitus in the honeymoon period, helping to maintain endogenous insulin secretion capacity 2

  • In Type B insulin resistance (a rare condition caused by autoantibodies against insulin receptors), rituximab has been successfully used as treatment, resulting in normalization of blood glucose levels and reduction or elimination of insulin requirements 3

  • Rituximab has been effective in treating insulin autoimmune syndrome (Hirata's disease), a rare hypoglycemic disorder characterized by insulin autoantibodies, leading to resolution of hypoglycemic episodes 4, 5

Potential Concerns in Specific Patient Populations

  • In patients with refractory nephrotic syndrome who receive rituximab, glucose metabolism disorders have been observed, but these appear to be primarily related to prior or concurrent use of diabetogenic medications (glucocorticoids and calcineurin inhibitors) rather than rituximab itself 6

  • When used in Waldenström's macroglobulinemia, rituximab can cause an IgM flare that may lead to hyperviscosity-related complications, but this is not directly related to glucose metabolism 1

Monitoring Recommendations

  • Standard monitoring during rituximab therapy includes CBC, hepatic and renal function tests, but does not specifically include blood glucose monitoring 1

  • For patients with pre-existing diabetes or risk factors for diabetes who are receiving rituximab, routine blood glucose monitoring would be prudent, particularly if they are also receiving concurrent medications that affect glucose metabolism (e.g., corticosteroids) 1

  • In patients receiving rituximab for autoimmune conditions affecting glucose metabolism (Type B insulin resistance, insulin autoimmune syndrome), close glucose monitoring is essential to track therapeutic response 3, 4, 5

Clinical Implications

  • For most patients receiving rituximab for standard indications (lymphoma, rheumatoid arthritis, etc.), no special glucose monitoring beyond routine care is required 1

  • In patients with pre-existing diabetes receiving rituximab, standard diabetes monitoring should continue, but no adjustment to diabetes management is typically needed specifically due to rituximab 1

  • Rituximab may actually be beneficial in rare autoimmune conditions affecting glucose metabolism, such as Type B insulin resistance and insulin autoimmune syndrome 3, 4, 5

  • When rituximab is used in combination with corticosteroids or other medications known to affect glucose metabolism, the effects on blood glucose should be attributed primarily to those agents rather than to rituximab itself 1, 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Successful treatment of type B insulin resistance with rituximab.

The Journal of clinical endocrinology and metabolism, 2015

Research

Novel Management of Insulin Autoimmune Syndrome with Rituximab and Continuous Glucose Monitoring.

The Journal of clinical endocrinology and metabolism, 2016

Research

Glucose metabolism disorders in children with refractory nephrotic syndrome.

Pediatric nephrology (Berlin, Germany), 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.